FDA approves Braftovi + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer (CRC) after prior therapy.- Pfizer
Related news and insights
Servier announced that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of Lonsurf (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.
Eli Lilly and Company announced that the FDA has granted approval of a new indication for Erbutix (cetuximab injection) in combination with Braftovi (encorafenib), marketed by Pfizer, Inc., for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Cardiff Oncology announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of PCM 075 (onvansertib) in KRAS-mutated metastatic colorectal cancer (mCRC) patients.